Pacific Northwest Chapter AACE Diabetes Day, September 30, 2017, Boise, ID

September 30, 2017

The Pacific Northwest Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Family / general practice and internal medicine physicians, advanced practice clinicians and other health care professionals living in Idaho who practice, or are interested in, the treatment of diabetes and related endocrine disease states.

Learning Objectives

  1. Practical considerations in disease management and outcomes
  2. Understanding the AACE glycemic control algorithm
  3. Understanding the AACE CVD risk factor modification algorithm
  4. Understand effective lifestyle intervention goals
  5. Develop effective lifestyle intervention strategies
  6. Understand the impact of lifestyle intervention in diabetes management
  7. Understand mechanism of action and glycemic effects of these agents
  8. Understanding SGLT2 inhibitors
  9. Review differences between DPP4 inhibitors and GLP1 agonists
  10. Understand the role of GLP-1 agonists in type 2 diabetes
  11. Develop an effective approach to initiating insulin therapy
  12. Understand how to advance and optimize insulin therapy
  13. Review recent data on therapeutic interventions for cardiovascular disease prevention in type 2 diabetes mellitus
  14. Update knowledge in changes of recommendations of CVD risk management
  15. Recognize new therapeutic targets for minimizing CVD risk
  16. Evaluate the latest technologies available for managing diabetes
  17. Recognize components of diabetes management systems recently in place
  18. Update knowledge in limitations of currently available technologies
  19. Better define specific approaches to management of diabetes in various patient presentations
  20. Understand how to approach evaluation of why current patient management approach is not optimally successful
  21. Recognize limitations of current technology
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 4.25 AMA
  • 4.25 Attendance
Course opens: 
09/30/2017
Course expires: 
09/30/2018
Event starts: 
09/30/2017 - 7:00am
Event ends: 
09/30/2017 - 1:00pm
Cost:
$0.00

Saturday, September 30, 2017

7:00 - 8:00 AMRegistration and Breakfast – Exhibit Hall Open
8:00 - 8:15 AMOpening Remarks and Program Objectives
8:15 - 8:45 AMApplication of the Diabetes Algorithm in a Patient 
Sherwin D’Souza, MD, FACE
Objectives:
  1. Practical considerations in disease management and outcomes
  2. Understanding the AACE glycemic control algorithm
  3. Understanding the AACE CVD risk factor modification algorithm
8:45 - 9:15 AMLifestyle Medicine 
Richard Christensen, MD
Objectives:
  1. Understand effective lifestyle intervention goals
  2. Develop effective lifestyle intervention strategies
  3. Understand the impact of lifestyle intervention in diabetes management
9:15 - 9:45 AMUpdate on Non-Insulin Agents in Type 2 Diabetes 
Sherwin D’Souza, MD, FACE
Objectives:
  1. Understand mechanism of action and glycemic effects of these agents
  2. Understanding SGLT2 inhibitors
  3. Review differences between DPP4 inhibitors and GLP1 agonists
9:45 - 10:00 AMQ & A 
10:00 - 10:30 AMBreak – Exhibit Hall Open 
10:30 - 11:00 AMInjectable Therapies for T2DM 
Richard Christensen, MD
Objectives:
  1. Understand the role of GLP-1 agonists in type 2 diabetes
  2. Develop an effective approach to initiating insulin therapy
  3. Understand how to advance and optimize insulin therapy
11:00 - 11:45 AMCardiovascular Risk Management in Patients with Type 2 Diabetes Mellitus 
Dace Trence, MD, FACE
Objectives:
  1. Review recent data on therapeutic interventions for cardiovascular disease prevention in type 2 diabetes mellitus
  2. Update knowledge in changes of recommendations of CVD risk management
  3. Recognize new therapeutic targets for minimizing CVD risk
11:45 - 12:15 PMAdvances in Diabetes Care Technologies 
Dace Trence, MD, FACE
Objectives:
  1. Evaluate the latest technologies available for managing diabetes
  2. Recognize components of diabetes management systems recently in place
  3. Update knowledge in limitations of currently available technologies
12:15 - 1:00 PMPatient Cases- Putting it All Together! 
Richard Christensen, MD, Sherwin D’Souza, MD, FACE
Dace Trence, MD, FACE

Objectives:
  1. Better define specific approaches to management of diabetes in various patient presentations
  2. Understand how to approach evaluation of why current patient management approach is not optimally successful
  3. Recognize limitations of current technology
1:00 PMAdjourn
Boise, ID
United States

Richard Christensen, MD
St. Luke's Idaho Endocrinology
Boise, ID

*Sherwin D'Souza, MD, FACE
St.Luke's Endocrinology and Humphreys Diabetes Center
Boise, ID

*Dace Trence, MD, FACE
Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition
Director, Endocrine Fellowship Program
Director, Diabetes Care Center
University of Washington, Seattle, WA

* Indicates both a member of the Program Committee and faculty.

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 4.25 AMA
  • 4.25 Attendance

Accreditation Period

Course opens: 
09/30/2017
Course expires: 
09/30/2018

Price

Cost:
$0.00
Please login or register to take this course.